Outcomes of drug-coated balloon endovascular angioplasty in the treatment of chronic femoropopliteal artery stenosis and occlusion
Main Article Content
Abstract
Background: Endovascular intervention has become the preferred treatment strategy for chronic femoropopliteal arterial stenosis and occlusion owing to its minimally invasive nature, low complication rate, rapid recovery, and long-term efficacy that is equivalent or superior to conventional open surgery. However, plain old balloon angioplasty (POBA) and metallic stent implantation still have significant limitations. Drug-coated balloons (DCB) were developed with the “leave nothing behind” strategy, preserving the vessel wall’s natural physiological structure after recanalization and avoiding the long-term risks associated with metallic implants.
Objective: To evaluate the 12-month short-term outcomes of endovascular paclitaxel-coated balloon angioplasty in the treatment of chronic femoropopliteal arterial stenosis and occlusion at Thong Nhat Hospital.
Patients and Methods: Retrospective descriptive case series of
Results: from June 2022 to June 2024, there were 122 patients underwent endovascular drug-coated balloon intervention for chronic femoropopliteal arterial stenosis and occlusion at Thong Nhat Hospital. Periprocedural clinical symptom improvement reached 93.4%. Immediately after the procedure, 54.1% of patients became completely asymptomatic, 4.1% had residual mild intermittent claudication, and 1.6% had residual moderate pain; no patients remained in Rutherford category 3 or 4. Hemodynamically, the mean ankle-brachial index (ABI) increased from 0.58 to 0.98 post-intervention, and triphasic flow was restored in 58.5% of cases. At 12-month follow-up, treatment efficacy remained high, with a primary patency rate of 74.2% and a limb salvage rate of 91.8%.
Conclusion: the “preferred endovascular intervention with drug-coated balloon” strategy is both reasonable and feasible in patients with chronic femoropopliteal arterial stenosis and occlusion, sustained long-term results, and reduced need for reintervention compared with alternative approaches.
Keywords
Chronic femoropopliteal arterial occlusive disease, paclitaxel-coated balloon, endovascular intervention
Article Details
References
2. Norgren L., Hiatt W. R., Dormandy J. A., Nehler M. R., Harris K. A., Fowkes F. G. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007;45 Suppl S:S5-67. Epub 2007/01/16. doi: 10.1016/j.jvs.2006.12.037. PubMed PMID: 17223489.
3. Tepe G., Laird J., Schneider P., et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131(5):495-502. Epub 2014/12/05. doi: 10.1161/circulationaha.114.011004. PubMed PMID: 25472980; PubMed Central PMCID: PMCPMC4323569.
4. Rosenfield K., Jaff M. R., White C. J., et al. Trial of a Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. N Engl J Med. 2015;373(2):145-53. Epub 2015/06/25. doi: 10.1056/NEJMoa1406235. PubMed PMID: 26106946.
5. Katsanos K., Spiliopoulos S., Kitrou P., Krokidis M., Karnabatidis D. Risk of Death Following Application of Paclitaxel-Coated Balloons and Stents in the Femoropopliteal Artery of the Leg: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Am Heart Assoc. 2018;7(24):e011245. Epub 2018/12/19. doi: 10.1161/jaha.118.011245. PubMed PMID: 30561254; PubMed Central PMCID: PMCPMC6405619.
6. Schneider P. A., Laird J. R., Doros G., et al. Mortality Not Correlated With Paclitaxel Exposure: An Independent Patient-Level Meta-Analysis of a Drug-Coated Balloon. J Am Coll Cardiol. 2019;73(20):2550-63. Epub 2019/01/29. doi: 10.1016/j.jacc.2019.01.013. PubMed PMID: 30690141.